What the FDA labels say about taking them together
Nilotinib and pantoprazole
Pantoprazole's FDA label of May 18, 2026 names nilotinib in its drug interactions section; nilotinib's label does not name pantoprazole itself but warns about its class (Proton pump inhibitors (PPIs)). The pantoprazole label: “Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.”
Check it at the source: the nilotinib FDA label on DailyMed (effective December 16, 2025, Novartis Pharmaceuticals Corporation); the pantoprazole FDA label on DailyMed (effective May 18, 2026, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.).
What does the nilotinib label say about pantoprazole?
Nilotinib's label does not name pantoprazole itself; it warns about its class (Proton pump inhibitors (PPIs)):
Nilotinib label, drug interactionsAvoid concomitant use with Tasigna. Use short-acting antacids or H2 blockers as an alternative to proton pump inhibitors.
Nilotinib label, drug interactionsProton Pump Inhibitors Concomitant use with a proton pump inhibitor (PPI) decreased nilotinib concentrations compared to Tasigna alone [see Clinical Pharmacology (12.3)], which may reduce Tasigna efficacy.
Source: FDA drug label (Tasigna), Novartis Pharmaceuticals Corporation, effective December 16, 2025 (SPL set 6093952a-5248-45cb-ad17-33716a411146), via openFDA; the full label on DailyMed
What does the pantoprazole label say about nilotinib?
Pantoprazole label, drug interactionsClinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. Intervention: Mycophenolate mofetil (MMF): Co-administration of pantoprazole sodium in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH …
Source: FDA drug label (Protonix Delayed-Release), Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective May 18, 2026 (SPL set 08098cb2-c048-4640-f387-6beec4a38936), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nilotinib | Pantoprazole | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Acid reflux and ulcers |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.0358 per tablet 40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once